A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]
Some stomach GISTs smaller than 2 cm may pose more risk than previously thought according to a new report from China.
Our first Chicago GIST Day of Learning (GDOL) was a huge success! Over 50 GISTers and their families gathered for a great day of learning, and sharing experiences. It was wonderful to get to meet so many new people and reconnect with old friends.
For many years, wild-type GIST tumors were a mystery. In 2007, Barbara Pasini, J. Aidan Carney, Constantine Stratakis and colleagues identified the first mutations in pediatric GIST tumors in a protein called succinate dehydrogenase (SDH). Coding (instructions) for making the SDH protein is contained in four subunits (genes), SDHA, SDHB, SHDC and SDHD. The group, led by Constantine Stratakis, initially reported mutations in three of the four subunits; SDHB, SHDC and SDHD. SHDA remained a mystery.
Co-Existing Conditions Co-existing conditions are medical illnesses or problematic conditions that a person has along with cancer, such as high blood pressure, diabetes, or depression. These conditions often influence how a person responds to treatment, [...]
Recently, the Life Raft Group began work on a survey project sponsored by Novartis Pharmaceuticals designed to assess knowledge and practices among patients and physicians regarding mutational analysis and plasma level testing.
Only six percent of GIST patients in the United States take advantage of testing that could be used to individualize their treatment according to a new article in the Annals of Oncology. Dr. Peter Pisters of MD Anderson Cancer Center in Houston, Texas and his colleagues reported results of the GIST reGISTry, a Novartis Pharmaceuticals-supported registry of 882 GIST patients in the United States.
January 6th, 2011 - By Jerry Call, LRG Science Coordinator The first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled to open [...]
KIT exon 11 and exon 9 mutations represent the two most common types of mutations (wild-type GIST is technically not a type of mutation but a lack of mutations) found in GIST patients. About 60 to 65 percent of GIST patients have a KIT exon 11 mutation and about 10 to15 percent have a KIT exon 9 mutation.
Dr. Christopher Corless discusses the value of mutational testing in treating GIST. Keep reading to hear this informative webcast.